Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHADRESH PATEL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1003913252
CMS profile
226942
Location
BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$599.21

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $599.21 34

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHADRESH PATEL

NPI 1003913252 · CMS profile ID 226942

Allopathic & Osteopathic Physicians / Internal Medicine

BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003913252?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003913252?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003913252?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003913252?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $599.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $12.8312/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020543927 CMS
PFIZER INC. $14.2110/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050104093 CMS
Novo Nordisk Inc $13.9110/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007355 CMS
Novo Nordisk Inc $23.3310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007437 CMS
GlaxoSmithKline, LLC. $14.5810/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002764227 CMS
Astellas Pharma US Inc $19.1010/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034560251 CMS
Novo Nordisk Inc $17.9209/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007389 CMS
Amgen Inc. $13.0009/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020543925 CMS
Radius Health, Inc. $14.2809/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024682775 CMS
GlaxoSmithKline, LLC. $14.1808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002764241 CMS
Novo Nordisk Inc $20.5408/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007401 CMS
Boston Scientific Corporation $14.9008/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022135817 CMS
AstraZeneca Pharmaceuticals LP $13.4708/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014633341 CMS
AstraZeneca Pharmaceuticals LP $18.2108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011277423 CMS
Lilly USA, LLC $13.9707/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031267139 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.9907/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000370223 CMS
GlaxoSmithKline, LLC. $18.1506/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002764217 CMS
Xeris Pharmaceuticals, Inc. $20.4806/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056445883 CMS
SANOFI-AVENTIS U.S. LLC $13.7606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049839575 CMS
ABBVIE INC. $22.6205/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998084001 CMS
Lilly USA, LLC $13.0005/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031289583 CMS
PFIZER INC. $18.3005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049351739 CMS
Novo Nordisk Inc $21.7805/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007425 CMS
Lilly USA, LLC $14.3804/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031286997 CMS
SANOFI-AVENTIS U.S. LLC $27.8603/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049839541 CMS
ABBVIE INC. $17.8803/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083999 CMS
Astellas Pharma US Inc $23.2603/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033991809 CMS
Amgen Inc. $21.4303/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020543923 CMS
Novo Nordisk Inc $15.4803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007367 CMS
Novo Nordisk Inc $21.0602/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007413 CMS
Novartis Pharmaceuticals Corporation $15.9702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992947051 CMS
Lilly USA, LLC $16.4302/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031271161 CMS
AstraZeneca Pharmaceuticals LP $14.8602/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015356175 CMS
Novo Nordisk Inc $17.0901/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001007379 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,622.73 32
PY2020 $547.52 37
PY2021 $1,137.72 67
PY2022 $676.49 44
PY2023 $599.21 34
PY2024 $518.32 33
PY2025 $749.06 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,003.52 172
PY2024 Principal investigator $421,638.32 23
PY2023 Principal investigator $317,080.95 398
PY2022 Principal investigator $272,453.35 534
PY2020 Principal investigator $3,172.98 4
PY2019 Principal investigator $1,202.28 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

172 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $500.00 12/26/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010076
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290348
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290350
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290352
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290354
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290356
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290358
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290360
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290362
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290364
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290366
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290368
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290370
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290372
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290374
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290376
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290378
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290380
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290382
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290384
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290386
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290388
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290390
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290392
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290394
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290396
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290398
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290400
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290402
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290404
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290406
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290408
Principal investigator 1 Seqirus USA Inc $788.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290410
Principal investigator 1 Seqirus USA Inc $400.40 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290420
Principal investigator 1 Seqirus USA Inc $400.40 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290422
Principal investigator 1 Seqirus USA Inc $400.40 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290428
Principal investigator 1 Seqirus USA Inc $788.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290430
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290434
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290438
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290458
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290460
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290462
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290464
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290466
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290468
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290470
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290472
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290474
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290476
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290478
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290480
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290482
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290484
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290486
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290488
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290490
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290492
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290494
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290496
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290498
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290501
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290504
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290506
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290508
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290510
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290512
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290514
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290516
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290518
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290521
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290524
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290526
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290528
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290530
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290532
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290534
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290536
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290538
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290540
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290542
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290544
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290546
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290548
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290550
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290552
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290554
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290556
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290558
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290560
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290564
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290566
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290568
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290570
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290572
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290574
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290576
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290578
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290580
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290582
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290584
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290586
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290588
Principal investigator 1 Seqirus USA Inc $3,119.20 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290590
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290592
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290594
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290596
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290598
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290600
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290602
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290604
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290606
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290608
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290610
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290612
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290614
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290616
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290618
Principal investigator 1 Seqirus USA Inc $1,064.00 12/18/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290620
Principal investigator 1 ModernaTX, Inc. $629.70 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947450
Principal investigator 1 ModernaTX, Inc. $6,169.67 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947454
Principal investigator 1 ModernaTX, Inc. $208.06 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947456
Principal investigator 1 ModernaTX, Inc. $602.64 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947458
Principal investigator 1 ModernaTX, Inc. $3,394.35 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947460
Principal investigator 1 ModernaTX, Inc. $3,508.26 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947462
Principal investigator 1 ModernaTX, Inc. $3,394.86 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947466
Principal investigator 1 ModernaTX, Inc. $1,901.40 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947470
Principal investigator 1 ModernaTX, Inc. $1,766.60 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947472
Principal investigator 1 ModernaTX, Inc. $3,080.40 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947474
Principal investigator 1 ModernaTX, Inc. $1,202.85 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947476
Principal investigator 1 ModernaTX, Inc. $1,050.90 11/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947482
Principal investigator 1 Seqirus USA Inc $3,846.60 11/12/2025 Non-covered Recipient Entity
Nature Coast Clinical Research - Crystal River
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810910
Principal investigator 1 Seqirus USA Inc $986.58 11/12/2025 Non-covered Recipient Entity
Nature Coast Clinical Research - Crystal River
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810915
Principal investigator 1 Seqirus USA Inc $4,274.00 10/31/2025 Non-covered Recipient Entity
Nature Coast Clinical Research - Crystal River
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810901
Principal investigator 1 Seqirus USA Inc $1,174.50 10/31/2025 Non-covered Recipient Entity
Nature Coast Clinical Research - Crystal River
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810905
Principal investigator 1 ModernaTX, Inc. $2,145.00 10/22/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947480
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/15/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947448
Principal investigator 1 ModernaTX, Inc. $300.00 10/15/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947464
Principal investigator 1 ModernaTX, Inc. $4,000.00 10/15/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947468
Principal investigator 1 ModernaTX, Inc. $750.00 10/15/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947478
Principal investigator 1 Seqirus USA Inc $2,000.00 09/25/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290436
Principal investigator 1 Seqirus USA Inc $4,925.00 09/25/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290440
Principal investigator 1 Seqirus USA Inc $11,000.00 09/25/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290442
Principal investigator 1 Seqirus USA Inc $110.98 09/03/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290424
Principal investigator 1 Seqirus USA Inc $111.30 09/03/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290426
Principal investigator 1 Seqirus USA Inc $946.80 09/03/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290432
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/01/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252947452
Principal investigator 1 ModernaTX, Inc. $59.28 08/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010078
Principal investigator 1 ModernaTX, Inc. $277.84 08/06/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010070
Principal investigator 1 ModernaTX, Inc. $327.60 08/06/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010098
Principal investigator 1 ModernaTX, Inc. $3,767.94 06/18/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010116
Principal investigator 1 ModernaTX, Inc. $6,817.20 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010068
Principal investigator 1 ModernaTX, Inc. $18,421.04 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010084
Principal investigator 1 ModernaTX, Inc. $1,419.63 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010088
Principal investigator 1 ModernaTX, Inc. $500.00 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010094
Principal investigator 1 ModernaTX, Inc. $151.36 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010100
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010102
Principal investigator 1 ModernaTX, Inc. $1,989.00 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010108
Principal investigator 1 ModernaTX, Inc. $81.90 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010112
Principal investigator 1 ModernaTX, Inc. $12,978.46 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010080
Principal investigator 1 ModernaTX, Inc. $8,517.78 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010092
Principal investigator 1 ModernaTX, Inc. $8,338.72 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010106
Principal investigator 1 ModernaTX, Inc. $500.00 04/10/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010118
Principal investigator 1 ModernaTX, Inc. $1,674.64 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010074
Principal investigator 1 ModernaTX, Inc. $7,350.72 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010096
Principal investigator 1 ModernaTX, Inc. $7,098.15 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010120
Principal investigator 1 ModernaTX, Inc. $6,279.90 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010090
Principal investigator 1 ModernaTX, Inc. $14,196.30 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010104
Principal investigator 1 ModernaTX, Inc. $8,299.20 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010110
Principal investigator 1 ModernaTX, Inc. $8,378.24 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010072
Principal investigator 1 ModernaTX, Inc. $14,653.10 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010082
Principal investigator 1 ModernaTX, Inc. $4,134.80 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010086
Principal investigator 1 ModernaTX, Inc. $12,776.67 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010114